Published in Mol Cancer Ther on June 01, 2002
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest (2008) 7.52
Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer (2013) 1.93
CD147 immunoglobulin superfamily receptor function and role in pathology. Exp Mol Pathol (2007) 1.77
Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas. Virchows Arch (2008) 1.71
Role of monocarboxylate transporters in human cancers: state of the art. J Bioenerg Biomembr (2012) 1.70
Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol (2010) 1.54
Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J (2008) 1.41
Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer (2011) 1.39
Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer (2011) 1.34
Expression of monocarboxylate transporters 1, 2, and 4 in human tumours and their association with CD147 and CD44. J Biomed Biotechnol (2010) 1.32
Histone acetylation regulates intracellular pH. Mol Cell (2012) 1.30
Metabolic targeting of lactate efflux by malignant glioma inhibits invasiveness and induces necrosis: an in vivo study. Neoplasia (2011) 1.29
Anticancer agents that counteract tumor glycolysis. ChemMedChem (2012) 1.17
Autophagy is a protective mechanism for human melanoma cells under acidic stress. J Biol Chem (2012) 1.17
Proton dynamics in cancer. J Transl Med (2010) 1.14
Importance of glycolysis and oxidative phosphorylation in advanced melanoma. Mol Cancer (2012) 1.10
Lactate and malignant tumors: a therapeutic target at the end stage of glycolysis. J Bioenerg Biomembr (2007) 1.08
Pyruvate fuels mitochondrial respiration and proliferation of breast cancer cells: effect of monocarboxylate transporter inhibition. Biochem J (2012) 1.05
Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. Neoplasia (2006) 1.02
Role of pHi, and proton transporters in oncogene-driven neoplastic transformation. Philos Trans R Soc Lond B Biol Sci (2014) 0.97
(31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan. NMR Biomed (2012) 0.95
Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin. NMR Biomed (2014) 0.94
Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer Metastasis Rev (2014) 0.91
Evaluation of endogenous acidic metabolic products associated with carbohydrate metabolism in tumor cells. Cell Biol Toxicol (2009) 0.89
Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization. J Transl Med (2014) 0.85
Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. BMC Cancer (2010) 0.84
Chromatin: a capacitor of acetate for integrated regulation of gene expression and cell physiology. Curr Opin Genet Dev (2014) 0.82
2-Aminophenoxazine-3-one and 2-amino-4,4α-dihydro-4α,7-dimethyl-3H-phenoxazine-3-one cause cellular apoptosis by reducing higher intracellular pH in cancer cells. Proc Jpn Acad Ser B Phys Biol Sci (2011) 0.82
Time-resolved fluorescence lifetime for cutaneous melanoma detection. Biomed Opt Express (2014) 0.81
Bonded Cumomer Analysis of Human Melanoma Metabolism Monitored by 13C NMR Spectroscopy of Perfused Tumor Cells. J Biol Chem (2015) 0.81
MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management. Oncotarget (2015) 0.80
Effects of hyperglycemia on lonidamine-induced acidification and de-energization of human melanoma xenografts and sensitization to melphalan. NMR Biomed (2015) 0.79
CD147 expression in advanced cutaneous squamous cell carcinoma. J Cutan Pathol (2012) 0.79
Lactate transporters in the context of prostate cancer metabolism: what do we know? Int J Mol Sci (2014) 0.79
The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters. Biochem J (2016) 0.78
(13)C MRS and LC-MS Flux Analysis of Tumor Intermediary Metabolism. Front Oncol (2016) 0.78
The antiangiogenic effects of a vascular endothelial growth factor decoy receptor can be monitored in vivo using contrast-enhanced ultrasound imaging. Mol Imaging (2014) 0.78
Dynamic scenario of metabolic pathway adaptation in tumors and therapeutic approach. Oncoscience (2015) 0.77
Prevention of carcinogenesis and development of gastric and colon cancers by 2-aminophenoxazine-3-one (Phx-3): direct and indirect anti-cancer activity of Phx-3. Int J Mol Sci (2013) 0.77
Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice. PLoS One (2016) 0.76
An integral approach to the etiopathogenesis of human neurodegenerative diseases (HNDDs) and cancer. Possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS). Neuropsychiatr Dis Treat (2008) 0.76
Significance of glycolytic metabolism-related protein expression in colorectal cancer, lymph node and hepatic metastasis. BMC Cancer (2016) 0.75
The altered glucose metabolism in tumor and a tumor acidic microenvironment associated with extracellular matrix metalloproteinase inducer and monocarboxylate transporters. Oncotarget (2016) 0.75
BI-1 enhances Fas-induced cell death through a Na+/H+-associated mechanism. BMB Rep (2014) 0.75
The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4. Cell Cycle (2016) 0.75
A cellular automaton model examining the effects of oxygen, hydrogen ions and lactate on early tumour growth. J Math Biol (2013) 0.75
Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res (2003) 2.24
Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell (2002) 1.71
Is human aging still mysterious enough to be left only to scientists? Bioessays (2002) 1.59
Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571. Cancer Biol Ther (2004) 1.55
VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys (2007) 1.55
Suprabasal Dsg2 expression in transgenic mouse skin confers a hyperproliferative and apoptosis-resistant phenotype to keratinocytes. J Cell Sci (2007) 1.39
Radiation-induced salivary gland dysfunction results from p53-dependent apoptosis. Int J Radiat Oncol Biol Phys (2009) 1.34
Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol (2006) 1.33
Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res (2005) 1.32
Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res (2003) 1.29
Interaction with LC8 is required for Pak1 nuclear import and is indispensable for zebrafish development. PLoS One (2009) 1.29
Biochemical and structural characterization of the Pak1-LC8 interaction. J Biol Chem (2008) 1.17
Progress in epidermolysis bullosa research: toward treatment and cure. J Invest Dermatol (2010) 1.16
Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res (2013) 1.13
Complex regulation of signal transducers and activators of transcription 3 activation in normal and malignant keratinocytes. Cancer Res (2004) 1.13
Novel use of zebrafish as a vertebrate model to screen radiation protectors and sensitizers. Int J Radiat Oncol Biol Phys (2005) 1.11
Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity. Proc Natl Acad Sci U S A (2011) 1.09
Metastasis-associated protein (MTA)1 enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes. Oncogene (2002) 1.08
Collection and visualization of dietary behavior and reasons for eating using Twitter. J Med Internet Res (2013) 1.07
The promise of digital (mobile) health in cancer prevention and treatment. Future Oncol (2013) 1.07
Specific sequences in p120ctn determine subcellular distribution of its multiple isoforms involved in cellular adhesion of normal and malignant epithelial cells. J Cell Sci (2002) 1.07
Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther (2008) 1.06
Restoration of radiation therapy-induced salivary gland dysfunction in mice by post therapy IGF-1 administration. BMC Cancer (2010) 1.05
Inhibition of p73 function by Pifithrin-alpha as revealed by studies in zebrafish embryos. Cell Cycle (2008) 1.03
Intracellular acidification abrogates the heat shock response and compromises survival of human melanoma cells. Mol Cancer Ther (2003) 1.03
E-cadherin loss promotes the initiation of squamous cell carcinoma invasion through modulation of integrin-mediated adhesion. J Cell Sci (2006) 1.03
In vivo radioprotection by the fullerene nanoparticle DF-1 as assessed in a zebrafish model. Clin Cancer Res (2006) 1.02
Cells expressing partially unfolded R789C/p.R989C type II procollagen mutant associated with spondyloepiphyseal dysplasia undergo apoptosis. Hum Mutat (2008) 1.00
Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer Res (2009) 0.99
A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res (2011) 0.98
Malignant transformation of immortalized HaCaT keratinocytes through deregulated nuclear factor kappaB signaling. Cancer Res (2006) 0.98
Coordinate control of cell cycle regulatory genes in zebrafish development tested by cyclin D1 knockdown with morpholino phosphorodiamidates and hydroxyprolyl-phosphono peptide nucleic acids. Nucleic Acids Res (2005) 0.97
Cell autonomous expression of inflammatory genes in biologically aged fibroblasts associated with elevated NF-kappaB activity. Immun Ageing (2008) 0.96
(31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan. NMR Biomed (2012) 0.95
Protocols for simulating the thermal component of fever: preclinical and clinical experience. Methods (2004) 0.94
Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin. NMR Biomed (2014) 0.94
Nuclear factor kappaB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos. Mol Cancer Ther (2009) 0.93
EGFR-dependent downregulation of Bim in epithelial cells requires MAPK and PKC-delta activities. Cancer Biol Ther (2006) 0.93
Sodium selenite increases the activity of the tumor suppressor protein, PTEN, in DU-145 prostate cancer cells. Nutr Cancer (2009) 0.91
Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma. BMC Genomics (2012) 0.91
Interleukin 6 mediates production of interleukin 10 in metastatic melanoma. Cancer Immunol Immunother (2011) 0.91
Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol (2008) 0.91
Differential regulation of p53 function by the N-terminal ΔNp53 and Δ113p53 isoforms in zebrafish embryos. BMC Dev Biol (2010) 0.91
Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res (2005) 0.90
Control of Glycolytic Flux by AMP-Activated Protein Kinase in Tumor Cells Adapted to Low pH. Transl Oncol (2012) 0.89
TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine. J Immunol (2002) 0.88
High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology (2009) 0.88
Prevention of radiation-induced salivary gland dysfunction utilizing a CDK inhibitor in a mouse model. PLoS One (2012) 0.87
Quercetin selectively inhibits bioreduction and enhances apoptosis in melanoma cells that overexpress tyrosinase. Nutr Cancer (2007) 0.87
Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am J Clin Oncol (2002) 0.87
Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. Hematol Oncol Clin North Am (2004) 0.87
Human pancreatic carcinoma cells secrete bioactive interleukin-18 after treatment with 5-fluorouracil: implications for anti-tumor immune response. Cancer Biol Ther (2005) 0.87
Hormesis and synergy: pathways and mechanisms of quercetin in cancer prevention and management. Nutr Rev (2010) 0.87
Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies. Cancer Biol Ther (2009) 0.86
Metaiodobenzylguanidine and hyperglycemia augment tumor response to isolated limb perfusion in a rodent model of human melanoma. Ann Surg Oncol (2004) 0.85
Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73. BMC Cancer (2010) 0.84
Effects of hyperthermia on p53 protein expression and activity. J Cell Physiol (2002) 0.83
A novel class of compounds with cutaneous wound healing properties. J Biomed Nanotechnol (2010) 0.83
Angiostatin induces intracellular acidosis and anoikis in endothelial cells at a tumor-like low pH. Endothelium (2002) 0.83
Kadota Fund International Forum 2004. Application of thermal stress for the improvement of health, 15-18 June 2004, Awaji Yumebutai International Conference Center, Awaji Island, Hyogo, Japan. Final report. Int J Hyperthermia (2008) 0.82
A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. Melanoma Res (2007) 0.82
The triterpenoid RTA 408 is a robust mitigator of hematopoietic acute radiation syndrome in mice. Radiat Res (2015) 0.81
Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother (2011) 0.80
Gene expression profiles as markers of aggressive disease-EGFR as a factor. Int J Radiat Oncol Biol Phys (2007) 0.80
Skinflammation and drug toxicity--a delicate balance. Sci Transl Med (2013) 0.80
Autoregulation of kinase dephosphorylation by ATP binding in AGC protein kinases. Cell Cycle (2012) 0.79
Effects of hyperglycemia on lonidamine-induced acidification and de-energization of human melanoma xenografts and sensitization to melphalan. NMR Biomed (2015) 0.79
Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol Immunother (2009) 0.79
Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model. Int J Radiat Oncol Biol Phys (2009) 0.79
Skin toxicity of targeted cancer agents: mechanisms and intervention. Future Oncol (2013) 0.79
Calculation of survival of patients with stage III melanoma. J Clin Oncol (2005) 0.79
Antisense inhibition of cyclin D1 expression is equivalent to flavopiridol for radiosensitization of zebrafish embryos. Int J Radiat Oncol Biol Phys (2006) 0.78
Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy. Cancer Immunol Immunother (2003) 0.78
Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma. J Surg Oncol (2011) 0.78
Tyrosinase overexpression promotes ATM-dependent p53 phosphorylation by quercetin and sensitizes melanoma cells to dacarbazine. Cell Oncol (2008) 0.77
PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma. Nucl Med Commun (2011) 0.77
Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice. Mol Cancer Ther (2004) 0.77
Effect of simultaneous inhibition of epidermal growth factor receptor and cyclooxygenase-2 in HER-2/neu-positive breast cancer. Clin Cancer Res (2006) 0.77
Tumor oxygenation and acidification are increased in melanoma xenografts after exposure to hyperglycemia and meta-iodo-benzylguanidine. Radiat Res (2003) 0.77
Factors controlling oxygen utilization. Adv Exp Med Biol (2005) 0.76
Thermal sensitisation by lonidamine of human melanoma cells grown at low extracellular pH. Int J Hyperthermia (2013) 0.76
Exploiting tyrosinase expression and activity in melanocytic tumors: quercetin and the central role of p53. Integr Cancer Ther (2010) 0.76
Predicting the future from trials of the past: epidermal growth factor receptor expression and outcome of fractionated radiation therapy trials. J Clin Oncol (2005) 0.75
Effect of mild hyperglycemia +/- meta-iodo-benzylguanidine on the radiation response of R3230 Ac tumors. Adv Exp Med Biol (2003) 0.75
Targeting the EGFR in neoplasia--more questions than answers. Int J Radiat Oncol Biol Phys (2004) 0.75
Keratinocyte culture in the absence of substrate attachment. Methods Mol Biol (2005) 0.75
Integration of investigative dermatology into the global biomedical research enterprise: past, present, and future. J Invest Dermatol (2012) 0.75
Whipsaw cancer treatments: the role of hormesis in endocrine and immune therapies. Semin Oncol (2006) 0.75
³¹P-MRS studies of melanoma xenografts with different metastatic potential. Adv Exp Med Biol (2011) 0.75